Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia

Cell Death & Disease
Wei LiChunyan Ji

Abstract

Tyrosine kinase inhibitor treatment of chronic myeloid leukemia (CML) has demonstrated beneficial effects. However, resistance to tyrosine kinase inhibitors and disease relapse are still a challenge for CML therapy. In this study, we analyzed bone marrow samples from 149 CML patients and 15 control donors, and investigated the affect of AF1q on CML cell survival and engraftment in vitro and in vivo. We found that AF1q/MLLT11 expression was significantly upregulated in CML patients, especially in CD34+ CML cells. Elevated AF1q expression was associated with disease progression. Knockdown of AF1q enhanced imatinib sensitivity, induced apoptosis, and suppressed growth in CML cells. Moreover, AF1q deficiency sensitized CD34+ CML cells to imatinib. In contrast, upregulation of AF1q promoted cell survival, protected CML cells from imatinib-induced apoptosis, and increased engraftment of CML cells in vivo. We further identified a positive correlation between AF1q and CD44 expression in chronic phase CML patients and CD34+ CML cells. Importantly, AF1q contributes to imatinib-resistance in CML by regulating the expression of CD44. These findings reveal a novel BCR-ABL-independent pathway, AF1q/CD44, involves imatinib resistance in CML, ...Continue Reading

References

Oct 10, 2003·The New England Journal of Medicine·John M Goldman, Junia V Melo
Dec 30, 2004·The Journal of Clinical Endocrinology and Metabolism·Caroline JacquesPascal Reynier
Jan 11, 2005·British Journal of Haematology·William TseTheodore Gooley
Sep 19, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Da-Qiang LiZhi-Min Shao
Sep 26, 2006·Nature Medicine·Daniela S KrauseRichard A Van Etten
Sep 26, 2006·Nature Medicine·Liqing JinJohn E Dick
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Oct 12, 2007·Breast Cancer Research and Treatment·Xin-Zhong ChangZhi-Ming Shao
Sep 19, 2008·Leukemia·N MisaghianJ A McCubrey
Dec 17, 2009·Clinical Lymphoma & Myeloma·Emma Nicholson, Tessa Holyoake
Dec 16, 2010·The Journal of Clinical Investigation·Amie S CorbinBrian J Druker
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge CortesHagop Kantarjian
Nov 22, 2013·Cancer Cell International·Guoqiang ChangTianxiang Pang
Dec 2, 2015·Proceedings of the National Academy of Sciences of the United States of America·Frida HolmCatriona H M Jamieson
Dec 22, 2015·Cellular and Molecular Life Sciences : CMLS·Yiguo Hu, Shaoguang Li

❮ Previous
Next ❯

Citations

Sep 22, 2019·Protein Expression and Purification·Nazimuddin KhanT Michael Sabo
Oct 8, 2019·Biochemical and Biophysical Research Communications·Tomiteru ToganoJino Park

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE84842

Methods Mentioned

BETA
flow cytometry
immunoprecipitation
density gradient centrifugation

Software Mentioned

GeneSignalNetwork

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis